Effects of HIV-1 infection on lymphocyte phenotypes in blood versus lymph nodes

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 5, 2005, Pages 507-518

  Yang, Otto O ^a,b,d   Ferbas, John J ^a   Hausner, Mary Ann ^a   Hultin, Lance E ^a   Hultin, Patricia M ^a   McFadden, David ^a   Sawicki, Mark ^a   Detels, Roger ^c   Majchrowicz, Martin ^a   Matud, Jose L ^a   Giorgi, Janis V ^a,b   Jamieson, Beth D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

Cd8+ T lymphocytes; HIV 1; Lymph node; Peripheral blood

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS INFECTION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; LYMPH NODES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTE SUBSETS; VIREMIA;

EID: 23244444710     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig. 1992;70:539-544.
2. Pantaleo G, Cohen OJ, Schacker T, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med. 1998;4:341-345.
3. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;332:209-216.
4. Simmonds P, Balfe P, Peutherer JF, et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol. 1990;64:864-872.
5. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
6. Matano T, Shibata R, Siemon C, et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol. 1998;72:164-169.
7. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283:857-860.
8. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003;77:2081-2092.
9. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol. 2001;75: 11983-11991.
10. Liu Z, Hultin LE, Cumberland WG, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry. 1996;26:1-7.
11. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
12. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346-355.
13. Altfeld M, van Lunzen J, Frahm N, et al. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest. 2002;109:837-843.
14. Killian MS, Monteiro J, Matud J, et al. Persistent alterations in the T-cell repertoires of HIV-1-infected and at-risk uninfected men. AIDS. 2004;18: 161-170.
15. Yang OO, Boscardin WJ, Matud J, et al. Immunologic profile of highly exposed yet HIV type 1-seronegative men. AIDS Res Hum Retroviruses. 2002;18:1051-1065.
16. Iyer SB, Hultin LE, Zawadzki JA, et al. Quantitation of CD38 expression using QuantiBRITE beads. Cytometry. 1998;33:206-212.
17. Westfall PH, Young SS. Resampling-Based Multiple Testing. New York: John Wiley & Sons; 1993.
18. Putter H, Heisterkamp SH, Lange JMA, et al. A Bayesian approach to parameter estimation in HIV dynamical models. Stat Med. 2002;21:2199-2214.
19. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997; 186:1407-1418.
20. Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106-111.
21. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379-385.
22. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8(+) T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061-1068.
23. Haridas V, McCloskey TW, Pahwa R, et al. Discordant expression of perform and granzyme A in total and HIV-specific CD8 T lymphocytes of HIV infected children and adolescents. AIDS. 2003;17:2313-2322.
24. Zhang D, Shankar P, Xu Z, et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perform and are not directly cytotoxic. Blood. 2003;101:226-235.
25. Heintel T, Sester M, Rodriguez MM, et al. The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS. 2002;16:1497-1501.
26. Andersson J, Kinloch S, Sonnerborg A, et al. Low levels of perform expression in CD8+ T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J Infect Dis. 2002; 185:1355-1358.
27. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:332-340.
28. Benito JM, Zabay JM, Gil J, et al. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:128-135.
29. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859-870.
30. Prince HE, Jensen ER. HIV-related alterations in CD8 cell subsets defined by in vitro survival characteristics. Cell Immunol. 1991;134:276-286.
31. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 1996;156:3509-3520.
32. Grimaldi JC, Balasubramanian S, Kabra NH, et al. CD38-mediated ribosylation of proteins. J Immunol. 1995;155:811-817.
33. Prabhakar P, Laboy JI, Wang J, et al. Effect of NADH-X on cytosolic glycerol-3-phosphate dehydrogenase. Arch Biochem Biophys. 1998;360: 195-205.
34. Ausiello CM, la Sala A, Ramoni C, et al. Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell Immunol. 1996;173:192-197.
35. Bofill M, Parkhouse RM. The increased CD38 expressed by lymphocytes infected with HIV-1 is a fully active NADase. Eur J Immunol. 1999;29: 3583-3587.
36. Ho HN, Hultin LE, Mitsuyasu RT, et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol. 1993; 150:3070-3079.
37. Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2002;30:33-40.
38. Rinaldo CR Jr, Huang XL, Fan Z, et al. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency. J Virol 2000;74:4127-4138.
39. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 1999;73:6721-6728.
40. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999;73:797-800.